A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.